Italian medical device maker Sorin Group (BIT:SRN) invested in early-stage company Enopace Biomedical to fund the development of a neuromodulation system for patients with congestive heart failure.
Enopace’s technology consists of an implantable neurostimulator that increases heart efficiency by reducing the workload placed on the left ventricle. Sorin Group’s $7 million investment will finance clinical studies and ongoing product development.